CIBC starts Profound Medical at OP, PT $3.50

CIBC starts Profound Medical at OP, PT $3.50

CIBC World Markets initiated coverage of Profound Medical (TSXV:PRN; OTCQX:PRFMF) with an “outperformer” rating and 12-to-18-month price target of $3.50. The stock closed at 85 cents on Nov. 15.

Read More

Oramed to conduct NASH study with oral insulin capsule

Oramed to conduct NASH study with oral insulin capsule

Oramed Pharmaceuticals (NASDAQ:ORMP) received approval from Israel's Ministry of Health to initiate an exploratory clinical study of its oral insulin capsule, ORMD-0801, in patients with nonalcoholic steatohepatitis (NASH).  

Read More

Leerink ups Mirati Therapeutics OP; PT $20

Leerink ups Mirati Therapeutics OP; PT $20

Leering upgraded Mirati Therapeutics (NASDAQ:MRTX) to “outperform” from “market perform” and raised its price target to $20 from $15, after the company re-prioritized its pipeline programs. The stock closed at $15.50 on Oct. 13.

Read More

Theralase researcher discovers potent anti-cancer drugs

Theralase researcher discovers potent anti-cancer drugs

Theralase Technologies (OTCQX:TLTFF; TSXV:TLT) recently identified a new platform of super potent anti-cancer drugs, or PDCs, discovered by Dr. Sherri McFarland, Professor, Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, the original inventor of the Theralase licensed ruthenium-based PDCs.

Read More

Clearside Biomedical presents DME data at AAO

Clearside Biomedical presents DME data at AAO

Clearside Biomedical (NASDAQ:CLSD) presented preliminary results from the exploratory HULK clinical trial of CLS-TA, its proprietary suspension formulation of the corticosteroid, triamcinolone acetonide, for suprachoroidal administration (suprachoroidal CLS-TA), with and without intravitreally injected EYLEA for the treatment of diabetic macular edema (DME).

Read More

IntelGenx seeks Health Canada approval for montelukast VersaFilm trial

IntelGenx seeks Health Canada approval for montelukast VersaFilm trial

IntelGenx (OTCQX:IGXT; TSXV:IGX) submitted a clinical trial application to Health Canada for approval to initiate a Phase 2a proof-of-concept study with montelukast in mild-to-moderate Alzheimer's disease (AD). 

Read More

Flex Pharma reports positive Phase 2 ALS cramping data

Flex Pharma reports positive Phase 2 ALS cramping data

Flex Pharma (NASDAQ:FLKS) announced positive topline data for FLX-787 from its placebo-controlled, crossover Australian trial in amyotrophic lateral sclerosis (ALS) patients with frequent muscle cramps.

Read More

Roth resumes coverage of IRIDEX at buy, PT $13

Roth resumes coverage of IRIDEX at buy, PT $13

Roth Capital Partners resumed coverage of IRIDEX (NASDAQ:IRIX) with a “buy” rating and $13 price target after the company reported modest upside to Roth’s prior revenue targets for the third quarter.

Read More

IntelGenx, RedHill Biopharma resubmit RIZAPORT NDA to FDA

IntelGenx, RedHill Biopharma resubmit RIZAPORT NDA to FDA

IntelGenx (OTCQX:IGXT; TSXV:IGX) and RedHill Biopharma (NASDAQ, TASE:RDHL) resubmitted the 505(b)(2) NDA to the FDA for RIZAPORT 10 mg, an oral thin-film formulation of rizatriptan for the treatment of acute migraines.

Read More

Oramed gets EU notice of broad patent claims for oral proteins

Oramed gets EU notice of broad patent claims for oral proteins

The European Patent Office has issued to Oramed Pharmaceuticals (NASDAQ, TASE:ORMP) a notice of intent to grant a patent for broader claims for its invention titled, “Methods and Compositions for Oral Administration of Proteins.”

Read More

Mateon updates Phase 1b AML data

Mateon updates Phase 1b AML data

Mateon Therapeutics (OTCQX:MATN) announced updated data from the fifth dose cohort of OX1222, a Phase 1b dose-ranging study of OXi4503 in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).

Read More

Clearside completes patient enrollment in Phase 2 DME trial

Clearside completes patient enrollment in Phase 2 DME trial

Clearside Biomedical (NASDAQ:CLSD) completed patient enrollment in the Phase 2 TYBEE clinical trial of suprachoroidal CLS-TA together with intravitreally administered Eylea for the treatment of diabetic macular edema (DME). 

Read More